Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avadel Pharmaceuticals plc

http://www.avadel.com

Latest From Avadel Pharmaceuticals plc

First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC

Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.

Clinical Trials Personalized Medicine

Provention Maps Possible Regulatory Path For Troubled Teplizumab

Provention has been working hard collecting necessary data for a potential BLA resubmission for teplizumab in patients at risk of developing type 1 diabetes after receiving a complete response letter in July. Hopes rest on a Type A meeting with the FDA in Q4.

Companies Regulation

Tibsovo Approval Is A Stepping Stone For Servier’s Longer-Term Oncology Strategy

The privately held company expects five US FDA approvals by 2026 and will focus on big-ticket targets like immune checkpoints and cell therapies, CEO David K. Lee told Scrip.

Business Strategies Cancer

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.

Deals M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Other Names / Subsidiaries
    • Avadel Specialty Pharmaceuticals, LLC
    • Éclat Pharmaceuticals, L.L.C.
    • FSC Pediatrics, Inc.
    • FSC Therapeutics, LLC
    • FSC Laboratories, Inc.
    • FSC Holdings, LLC
    • Flamel Technologies
UsernamePublicRestriction

Register